我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

冠脉内注射替罗非班治疗急性冠脉综合征 介入术后无复流的有效性和安全性

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2009年第1期
页码:
66-68
栏目:
临床研究
出版日期:
2009-02-28

文章信息/Info

Title:
Efficacy and safety of intracoronary tirofiban on no-reflow patients after PCI in acute coronary syndrome
作者:
卫丽; 李学奇; 金恩泽; 王晓云
哈尔滨医科大学附属第四医院心脏中心，黑龙江 哈尔滨 150001
Author(s):
WEI Li;  LI Xue-qi;  JIN En-ze;  WANG Xiao-yun
Heart Center, Fourth Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China
关键词:
急性冠脉综合征; 替罗非班; 无复流; 介入治疗
Keywords:
acute coronary syndrome;  tirofiban;  no-reflow;  percutaneous coronary intervention
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 评价冠脉内注射国产盐酸替罗非班对急性冠脉综合征（ACS）介入术后无复流患者TIMI血流的影响及安全性。方法 ACS患者行支架植入术后判定无复流者46例，随机分为替罗非班组(冠脉内注射盐酸替罗非班10 μg/kg)26例，硝酸甘油组(冠脉内注射硝酸甘油200 μg)20例。观察给药后30 min TIMI血流分级及校正的TIMI计帧数（CTFC），2 d后安全性的终点及30 d主要不良心血管事件(MACE)发生率。结果 替罗非班组介入术后无复流患者TIMI Ⅲ级血流获得率显著高于硝酸甘油组(65% vs 30%,P<0.05)；校正的TIMI计帧数显示替罗非班组血流快于硝酸甘油组［(72±19) vs (93±22)，P<0.01］，两组患者30 d的MACE发生率替罗非班组低于硝酸甘油组(4% vs 20%)，但差异未达到显著水平。替罗非班组出血不良反应较硝酸甘油组略高（12% vs 10%），但差别无统计学意义，两组均未见血小板减少。结论 冠脉内注射国产盐酸替罗非班治疗ACS介入术后无复流患者是有效和安全的。
Abstract:
AIM To evaluate the efficacy and safety of intracoronary tirofiban on TIMI flow in acute coronary syndrome (ACS) with no-reflow after PCI. METHODS Forty-six ACS patients with no-reflow after stenting were randomized to tirofiban group (intracoronary tirofiban, 10 μg/kg, n=26) and nitroglyceride group (intracoronary nitroglyceride, 200 μg, n=20). Targets to be observed consisted of corrected TIMI frame count (CTFC), TIMI flow at 30-minute post-medication, safety end-points of 2-day post-PCI and incidence of major adverse cardiovascular events (MACE) of 30-day post-PCI. RESULTS The TIMI 3 ratio in tirofiban group was markedly higher than that in nitroglyceride group (65% vs 30%, P<0.05). CTFC showed that the coronary blood flow in tirofiban group was faster than that in nitroglyceride group (72±19 vs 93±22, P<0.01). No significant difference was found in the incidence of MACE of 30-day post-PCI and bleeding events between tirofiban and nitroglyceride groups (4% vs 20%; 12% vs 10%). No thrombocytopenia was observed in the two groups. CONCLUSION The administration of intracoronary tirofiban is effective and safe for ACS patients with no-reflow after PCI.

参考文献/References

[1］ 陈跃峰,杨跃进. 经皮冠状动脉介入治疗术后的无再流现象［J］. 心血管病学进展, 2005, 26(1):28-32.
［2］ Tanaka A, Kawarabayashi T, Nishibori Y, et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction［J］. Circulation, 2002, 105(18):2148-2152.
［3］ 刁繁荣，吕安林，李军杰，等. 雷帕霉素-替罗非班复合药物涂层支架预防支架内血栓和再狭窄的实验研究［J］. 心脏杂志， 2007, 19（4）:384-387.
［4］ Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)［J］. J Am Coll Cardiol, 2004, 44(3):E1-E211.
［5］ Yip HK, Wu CJ, Chang HW, et al. Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes［J］. Chest, 2003, 124(3):962-968.
［6］ Yang TY, Chang ST, Chung CM, et al. Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment［J］. Int Heart J, 2005, 46(1):139-145.
［7］ Jones CJ, DeFily DV, Patterson JL, et al. Endothelium-dependent relaxation competes with alpha-1 and alpha-2 adrenergic constriction in the canine epicardial coronary microcirculation［J］. Circulation, 1993, 87(4):1264-1274.
［8］ Elmouchi DA, Bates ER. Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes［J］. Minerva Cardioangiol, 2003, 51(5):547-560.
［9］ Heitzer T, Ollmann I, Kke K, et al. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease［J］. Circulation, 2003, 108(5):536-541.
［10］Desai M, Lucore CL. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-asssociated thrombocytopenia 10 months earlier［J］. J Invasive Cardiol, 2000, 12(2):109-112.

备注/Memo

备注/Memo:
收稿日期：2008-1-7.作者简介：卫丽，主治医师，硕士Email:lsc1972@163.com
更新日期/Last Update: 2009-04-02